Anatomic Pathology Market: as targeted oncology therapy keeps expanding the list of biomarkers a tumour must be tested for before treatment can begin, every companion diagnostic mandate now turns a single tissue biopsy into a multi-assay decision point rather than a single stain, so pathology is shifting from a descriptive discipline into a mandatory gateway for prescribing, and competitive advantage is moving toward platforms that can add validated AI-assisted assays fastest rather than those that simply process the most slides.

The global anatomic pathology market size was USD 16.84 Billion in 2025 and is expected to register a revenue CAGR of 8.6% during the forecast period. Market revenue growth is driven by factors such as rising global cancer incidence, the expansion of companion diagnostic mandates linking tissue biomarker status to targeted therapy eligibility, and the regulatory momentum behind AI-assisted digital pathology tools. The first driving factor is the scale of global cancer incidence. The WHO Global Cancer Observatory estimated approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with new cancer cases projected to rise to 35 million by 2050 as populations age. The second driving factor is the structurally growing volume of mandatory companion diagnostic testing. Over 60 FDA-approved companion diagnostics are commercially available as of 2025, each requiring tissue-based biomarker confirmation before its linked targeted therapy can be prescribed. The third driving factor is the acceleration of FDA regulatory activity around AI-assisted digital pathology tools. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single validated digital pathology platform accumulates additional cleared or designated AI algorithms on the same installed scanner and image management infrastructure, which converts one regulatory milestone into a widening set of billable diagnostic use cases without new capital equipment. Once a laboratory adopts a cleared digital pathology image management system, each additional FDA-authorized or breakthrough-designated AI algorithm adds a new billable diagnostic or companion diagnostic use case to the same whole-slide-imaging infrastructure, so testing revenue per scanner compounds as the platform's authorized algorithm set widens around the same digitised slide archive. As a result, demand and revenue share are concentrating around platforms that hold the broadest set of FDA-authorized pathology AI algorithms, and the forecast tilts toward laboratories running multi-algorithm digital pathology platforms rather than single-purpose IHC staining alone. For instance, in July 2025, Artera received FDA De Novo authorization for ArteraAI Prostate, the first FDA-authorized prognostic whole-slide-imaging AI device, one of a widening set of AI-authorized pathology algorithms that, together with PathAI's Predetermined Change Control Plan-authorized AISight Dx platform, now lets laboratories add new AI capability to already-installed digital pathology infrastructure without a new scanner purchase. These are some of the key factors driving revenue growth of the market.

Because the American Society for Clinical Pathology has documented double-digit vacancy rates at clinical pathology positions in the United States, and the WHO identifies pathologist shortages as a significant barrier to cancer diagnosis capability in low- and middle-income countries, laboratory throughput is capped by specialist headcount even where advanced instruments are already installed.

Digital pathology capital cost is a second constraint, because whole-slide scanners and enterprise image management infrastructure require a substantial upfront investment that many hospital pathology departments cannot justify until digital workflows demonstrate a clear return through AI-assisted diagnostic efficiency.

Reimbursement lag is a third constraint, since AI-assisted pathology algorithms frequently receive FDA authorization before payers establish a dedicated reimbursement code for the AI-assisted portion of the diagnostic workflow, so laboratories often absorb the technology cost without a corresponding new revenue line in the near term.

These factors substantially limit anatomic pathology market growth over the forecast period.

The clearest driver of demand is the structurally growing volume of mandatory companion diagnostic testing tied to targeted therapy prescribing. A companion diagnostic works by confirming that a specific tissue biomarker is present before its linked targeted therapy can be legally prescribed, so every new targeted therapy approval that carries a companion diagnostic requirement creates a corresponding new mandatory testing event rather than an optional one. Over 60 FDA-approved companion diagnostics are commercially available as of 2025, and the WHO Global Cancer Observatory estimated approximately 20 million new cancer cases worldwide in 2022, with cases projected to rise to 35 million by 2050. In April 2025, Roche received FDA breakthrough device designation for its VENTANA TROP2 (EPR20043) RxDx Device, the first breakthrough designation granted for a computational pathology companion diagnostic, and in April 2025, Paige received breakthrough device designation for PanCancer Detect, an AI tool identifying both common and rare cancer variants across multiple tissue types. The effect on the market is that IHC and companion diagnostic testing volume grows in direct proportion to targeted therapy approvals rather than to cancer incidence alone. These are some of the key factors driving revenue growth of the market.

The second driver is the accelerating pace of FDA clearance and breakthrough designation for AI algorithms that analyse digital whole-slide pathology images. Digital pathology AI works by extracting prognostic or predictive signal directly from a scanned tissue image, and because that signal can be generated from a slide a laboratory has already digitised, each newly authorized algorithm adds a billable diagnostic capability to existing whole-slide-imaging infrastructure rather than requiring new tissue collection. In January 2025, Modella AI's PathChat DX, a generative AI diagnostic co-pilot, received FDA breakthrough device designation, and between January and March 2025 the FDA released draft and final guidance on AI-enabled medical device lifecycle management specifically to support this category. In July 2025, Artera received FDA De Novo authorization for ArteraAI Prostate, the first FDA-authorized prognostic whole-slide-imaging AI device, predicting androgen-deprivation-therapy benefit directly from a biopsy slide. The effect on the market is that digital pathology revenue is shifting from scanner and archive infrastructure sales toward recurring per-algorithm diagnostic licensing. These are some of the key factors driving revenue growth of the market.

Artera's July 2025 FDA authorization for ArteraAI Prostate is the first FDA-authorized prognostic whole-slide-imaging AI device. It predicts treatment benefit directly from a biopsy slide already sitting in a laboratory's digital archive.

The third driver is the expansion of molecular companion diagnostic clearances that require pathology laboratories to run tests beyond traditional immunohistochemistry. A molecular companion diagnostic such as a microsatellite instability or genomic profiling panel works by detecting a molecular signature that IHC staining cannot resolve on its own, so laboratories seeking to run the full menu of biomarker tests required by modern targeted therapy protocols must add molecular pathology capability alongside their existing IHC infrastructure. In August 2025, Biocartis received FDA premarket approval for its Idylla CDx MSI Test, a companion diagnostic for microsatellite instability detection, and in September 2025, Tempus AI received FDA 510(k) clearance for its xR IVD genomic profiling panel. The effect on the market is that molecular pathology is becoming a required rather than optional service line at reference laboratories seeking to retain full companion diagnostic testing contracts. These are some of the key factors driving revenue growth of the market.

However, the anatomic pathology market faces severe adoption constraints from the global pathologist workforce shortage and the high capital cost of digital pathology infrastructure.

Because the American Society for Clinical Pathology has documented double-digit vacancy rates at clinical pathology positions in the United States, and the WHO identifies pathologist shortages as a significant barrier to cancer diagnosis capability in low- and middle-income countries, laboratory throughput remains capped by specialist headcount even as AI-assisted tools add new diagnostic capability to the same installed infrastructure.

Digital pathology capital cost compounds this, because whole-slide scanners and enterprise image management infrastructure require a substantial upfront investment that many hospital pathology departments cannot justify until digital workflows demonstrate a clear return through AI-assisted diagnostic efficiency, so adoption remains concentrated among larger academic and reference laboratory networks.

Reimbursement lag is the third constraint, since AI-assisted pathology algorithms frequently receive FDA authorization before payers establish a dedicated reimbursement code for the AI-assisted portion of the workflow, so laboratories often absorb the technology cost without a corresponding new revenue line until coding catches up.

These factors substantially limit anatomic pathology market growth over the forecast period.

Based on product and service, the global anatomic pathology market is segmented into instruments, consumables, software and AI, and reference laboratory services. Consumables hold the largest revenue share, because every tissue sample processed consumes antibodies, reagents, stains, slides, and cassettes regardless of which instrument or software platform a laboratory uses, which suits a market where testing volume, not capital equipment turnover, drives the largest revenue line. Instruments remain a necessary one-time or periodic capital purchase and are the smallest revenue category, since a single automated stainer or scanner supports years of recurring consumable and software revenue once installed. Software and AI is expected to register the fastest revenue growth rate in the global anatomic pathology market over the forecast period, driven by the FDA's accelerating pace of algorithm authorizations such as Artera's ArteraAI Prostate and PathAI's AISight Dx, which is why laboratories are increasingly licensing per-algorithm diagnostic capability rather than only purchasing new hardware.

Companion diagnostics application is expected to account for a significantly large revenue share in the global anatomic pathology market during the forecast period

Based on application, the global anatomic pathology market is segmented into disease diagnosis, companion diagnostics, and research and drug development. Disease diagnosis holds the largest revenue share, because routine oncology biopsy and surgical pathology testing remains the base volume driver across every hospital and reference laboratory, which suits a market where general diagnostic testing underpins the infrastructure that companion diagnostic testing then runs on top of. Companion diagnostics is expected to register the fastest revenue growth rate in the global anatomic pathology market over the forecast period, driven by the more than 60 FDA-approved companion diagnostics now commercially available and the steady pace of new approvals such as Roche's TROP2 IHC breakthrough designation, which is why Roche, Biocartis, and Tempus AI are all expanding their molecular and IHC companion diagnostic menus simultaneously.

Based on technology, the global anatomic pathology market is segmented into immunohistochemistry and histopathology, digital pathology and whole slide imaging, molecular pathology, and AI-assisted image analysis. Immunohistochemistry and histopathology hold the largest revenue share today, because it remains the foundational technology underlying both routine diagnosis and most current companion diagnostic assays, which ties directly back to the mandatory testing volume described in the market's primary demand driver. AI-assisted image analysis is expected to register the fastest revenue growth rate in the global anatomic pathology market over the forecast period, driven by the FDA's expanding pace of breakthrough device designations and 510(k) clearances for pathology AI algorithms, which is why PathAI, Artera, and Modella AI are each racing to expand their authorized algorithm portfolios.

Based on regional analysis, the anatomic pathology market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA companion diagnostic and pathology AI algorithm authorizations creates a direct testing-to-prescribing pathway, and because Roche, Danaher, Labcorp, and Quest Diagnostics all maintain their primary commercial and regulatory presence in the US market. Quest Diagnostics reported USD 9.87 Billion in FY2024 revenue and Laboratory Corporation of America reported USD 13.01 Billion in FY2024 revenue, anchoring a domestic reference laboratory infrastructure large enough to sustain multiple competing digital pathology AI platforms simultaneously. The concentration of FDA clearance and breakthrough designation activity in the country also means new pathology AI algorithms are typically authorized in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Leica Biosystems, a Danaher company headquartered in Germany, maintains a strong European digital pathology presence through its Aperio scanner and HALO AP image management portfolio. The result is steady rather than rapid growth, shaped more by national health system procurement cycles and EU IVDR compliance timelines than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising cancer incidence and expanding reference laboratory infrastructure. Japan is the earlier-launch market for advanced digital pathology platforms in the region, which leaves more room for growth than in the already digitised North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private reference laboratory networks driving early adoption of digital pathology and companion diagnostic testing among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the antibodies, reagents, and precision scanning instrumentation that Latin American pathology laboratories depend on, an effect expected to run through 2026 and slow anatomic pathology adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional reference laboratory hubs represent the primary investment centres for anatomic pathology adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the pathologist workforce and laboratory infrastructure needed to support companion diagnostic testing at scale.